Federal grants to HDT Bio Corp
HDT Bio Corp in Seattle, Washington received $13.3 million in federal grants from fiscal 2021 to 2025, across 12 awards. Its largest program was Allergy and Infectious Diseases Research, with $9.8 million. In fiscal 2025 it was awarded $2.3 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$13.3 million
- Awards12
- Awarded in FY 2025$2.3 million
- Largest award$2.9 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 5 | $2.2 million |
| FY 2022 | 4 | $3.5 million |
| FY 2023 | 5 | $2.0 million |
| FY 2024 | 4 | $3.3 million |
| FY 2025 | 2 | $2.3 million |
Programs that fund HDT Bio Corp
| Program | Awards | Amount |
|---|---|---|
| Allergy and Infectious Diseases Research | 9 | $9.8 million |
| Military Medical Research and Development | 1 | $2.7 million |
| Cancer Detection and Diagnosis Research | 1 | $399,285 |
| Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases | 1 | $299,984 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 11 | $10.5 million |
| Department of Defense | 1 | $2.7 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Engineering the immune response of a self-replicating and adjuvanting rna HIV-1VACCINE - project summary/abstract a key requirement for HIV-1 vaccine development is the induction of broadly neutralizing antibodies (BNABS) targeting the HIV-1 envelope (ENV) spike. The BG505 sosip.664 GP140 soluble ti | Allergy and Infectious Diseases Research | April 9, 2021 | $2.9 million |
| Development of a temperature-stable broad-spectrum antiviral for respiratory viral pathogens | Military Medical Research and Development | July 11, 2022 | $2.7 million |
| Immunological mechanism of muscle-localizing self-replicating rna vaccines - project summary/abstract as evident in the ongoing “tripledemic” of severe acute respiratory SYNDROME-CORONAVIRUS-2, respiratory syncytial virus, and influenza virus, as well as re-emergence of enterovirus D68, virus infect | Allergy and Infectious Diseases Research | September 13, 2024 | $2.2 million |
| Engineering the immune response of a self-replicating and adjuvanting rna HIV-1VACCINE - project summary/abstract a key requirement for HIV-1 vaccine development is the induction of broadly neutralizing antibodies (BNABS) targeting the HIV-1 envelope (ENV) spike. The BG505 sosip.664 GP140 soluble ti | Allergy and Infectious Diseases Research | May 6, 2024 | $2.0 million |
| Rna vaccine innovations for tb: targeting the mucosa - project summary/abstract our team - in collaboration with other vaccine developers - has been actively involved in tuberculosis (TB) vaccine discovery for the past three decades and led the team that developed the M72 vaccine that has provided p | Allergy and Infectious Diseases Research | April 22, 2022 | $1.6 million |
| Targeting and imaging ovarian cancer with junction opener conjugated-lipid iron oxide nanoparticles (joc-lions) - project summary/abstract effective targeted treatments are needed to improve survival of patients with late stage ovarian and other solid tumor cancers of epithelial origin. Epithelial c | Cancer Detection and Diagnosis Research | August 27, 2021 | $399,285 |
| PA21259, sbir phase i, developing a rig-i agonist to prevent COVID-19 | Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases | August 30, 2023 | $299,984 |
| Development of an adaptable rna vaccine against enterovirus D68 infection for the prevention of acute flaccid myelitis - project summary: first identified in California in 2012, acute flaccid myelitis in children, associated with enterovirus D68 (EV-D68) infection, has been increasing in incidence w | Allergy and Infectious Diseases Research | September 2, 2021 | $299,976 |
| Development of a single-dose self-amplifying rna vaccine for boosting pre-existing influenza virus immunity, driving b and t cell responses to conserved targets - project summary while a universal influenza vaccine, providing life-long protective immunity against all current and future drifted and s | Allergy and Infectious Diseases Research | May 10, 2022 | $292,050 |
| Development of a rig-i agonist rna as a cure for chronic hepatitis b - project summary: despite the availability of a safe and effective vaccine, hepatitis b virus (HBV) continues to be a major problem, chronically infecting ~300 million people worldwide and causing more than 500,000 deaths per year | Allergy and Infectious Diseases Research | April 14, 2023 | $275,211 |
Questions people ask
How much federal grant money does HDT Bio Corp get?
$13.3 million in 12 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives HDT Bio Corp the most?
The Department of Health and Human Services, with $10.5 million in 11 awards. The Department of Defense follow.
What is HDT Bio Corp's largest federal grant?
$2.9 million under Allergy and Infectious Diseases Research, with its first action in the period on April 9, 2021. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund HDT Bio Corp?
Its largest are Allergy and Infectious Diseases Research, Military Medical Research and Development and Cancer Detection and Diagnosis Research.
Other grant recipients in Seattle
- University of Washington
- Central Puget Sound Regional Transit Authority
- Fred Hutchinson Cancer Center
- King County Metro Transit
- Port of Seattle
- Seattle Children's Hospital
- Allen Institute
- Seattle Housing Authority
Largest federal grant recipients in Washington · Federal grants in Washington